180 related articles for article (PubMed ID: 15099965)
21. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
Rodriguez M; Rose PG
Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
Elkas JC; Winter WE; Chernofsky MR; Sunde J; Bidus MA; Bernstein S; Rose GS
Gynecol Oncol; 2007 Feb; 104(2):422-7. PubMed ID: 16996118
[TBL] [Abstract][Full Text] [Related]
23. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Bolis G; Scarfone G; Tateo S; Mangili G; Villa A; Parazzini F
Gynecol Oncol; 2001 Jan; 80(1):13-5. PubMed ID: 11136562
[TBL] [Abstract][Full Text] [Related]
24. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Markman M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
Bhoola SM; Coleman RL; Herzog T; Morris R; Bryant C; Estes JM; Alvarez RD
Gynecol Oncol; 2004 Dec; 95(3):564-9. PubMed ID: 15581964
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
[TBL] [Abstract][Full Text] [Related]
27. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.
Park S; Ahn MJ; Ahn JS; Lee J; Hong YS; Park BB; Lee SC; Hwang IG; Park JO; Lim H; Kang WK; Park K
Lung Cancer; 2007 Oct; 58(1):116-22. PubMed ID: 17624473
[TBL] [Abstract][Full Text] [Related]
29. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
[TBL] [Abstract][Full Text] [Related]
30. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer.
Kellokumpu-Lehtinen P; Lantto A; Kokko R; Elomaa L; Järvenpää R; Lehtinen R; Blomqvist C
Int J Clin Pharmacol Res; 2002; 22(2):47-53. PubMed ID: 12503775
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
35. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.
Beddoe AM; Dottino PR; Cohen CJ
Mt Sinai J Med; 1993 Sep; 60(4):311-6. PubMed ID: 8232377
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
38. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
[TBL] [Abstract][Full Text] [Related]
39. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
40. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]